DexCom (NASDAQ:DXCM) Given "Hold (C-)" Rating at Weiss Ratings

Key Points

• DexCom received a "hold (C-)" rating from Weiss Ratings, with multiple analysts reaffirming "buy" ratings and various price targets ranging from $94.00 to $106.00.
• The stock traded at $70.33, experiencing significant trading volume, with a market cap of $27.58 billion and a price-to-earnings ratio of 48.84.
• Insider transactions revealed significant stock sales, with the company insiders owning only 0.32% of the stock, indicating lower insider confidence.

DexCom (NASDAQ:DXCM - Get Free Report)'s stock had its "hold (c-)" rating reissued by research analysts at Weiss Ratings in a research note issued to investors on Friday,Weiss Ratings reports.

DXCM has been the subject of a number of other research reports. Cowen reaffirmed a "buy" rating on shares of DexCom in a research note on Friday. Argus started coverage on shares of DexCom in a report on Thursday, August 21st. They set a "buy" rating and a $100.00 price target for the company. Wall Street Zen lowered shares of DexCom from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 10th. Truist Financial lowered their price target on shares of DexCom from $102.00 to $94.00 and set a "buy" rating for the company in a report on Wednesday, October 15th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $106.00 price target on shares of DexCom in a report on Monday, September 29th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, DexCom has an average rating of "Moderate Buy" and an average price target of $96.40.

DexCom Price Performance

NASDAQ:DXCM traded down $0.73 during mid-day trading on Friday, hitting $70.33. 3,161,832 shares of the stock traded hands, compared to its average volume of 4,630,355. The business's 50-day moving average price is $72.37 and its 200 day moving average price is $77.78. The company has a market cap of $27.58 billion, a PE ratio of 48.84, a price-to-earnings-growth ratio of 1.49 and a beta of 1.47. DexCom has a 12-month low of $57.52 and a 12-month high of $93.25. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping analysts' consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The business had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. During the same quarter in the previous year, the company earned $0.43 EPS. The business's quarterly revenue was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. On average, analysts expect that DexCom will post 2.03 EPS for the current fiscal year.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 1,466 shares of the company's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $80.00, for a total value of $117,280.00. Following the completion of the transaction, the executive vice president directly owned 105,223 shares in the company, valued at approximately $8,417,840. This represents a 1.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark G. Foletta sold 2,750 shares of the company's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $81.06, for a total transaction of $222,915.00. Following the completion of the transaction, the director owned 51,121 shares of the company's stock, valued at $4,143,868.26. This trade represents a 5.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,849 shares of company stock valued at $564,733 over the last quarter. Company insiders own 0.32% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in DXCM. Brighton Jones LLC raised its holdings in DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock worth $1,290,000 after purchasing an additional 11,946 shares in the last quarter. Oppenheimer & Co. Inc. increased its stake in shares of DexCom by 4.8% in the 1st quarter. Oppenheimer & Co. Inc. now owns 21,225 shares of the medical device company's stock worth $1,449,000 after acquiring an additional 974 shares in the last quarter. Golden State Wealth Management LLC increased its stake in shares of DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after acquiring an additional 264 shares in the last quarter. Alpine Bank Wealth Management bought a new position in shares of DexCom in the 1st quarter worth about $40,000. Finally, Robeco Institutional Asset Management B.V. increased its stake in shares of DexCom by 936.3% in the 1st quarter. Robeco Institutional Asset Management B.V. now owns 236,284 shares of the medical device company's stock worth $16,136,000 after acquiring an additional 213,483 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.